PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments
Haubner R, Maschauer S, Prante O (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Hindawi Publishing Corporation
Book Volume: 2014
Pages Range: 871609
DOI: 10.1155/2014/871609
Abstract
Noninvasive determination of integrin expression has become an interesting approach in nuclear medicine. Since the discovery of the first 18F-labeled cyclic RGD peptide as radiotracer for imaging integrin ?v?3 expression in vivo, there have been carried out enormous efforts to develop RGD peptides for PET imaging. Moreover, in recent years, additional integrins, including ?5?1 and ?v?6 came into the focus of pharmaceutical radiochemistry. This review will discuss the tracers already evaluated in clinical trials and summarize the preliminary outcome. It will also give an overview on recent developments to further optimize the first-generation compounds such as [18F]Galacto-RGD. This includes recently developed 18F-labeling strategies and also new approaches in 68Ga-complex chemistry. Furthermore, the approaches to develop radiopharmaceuticals targeting integrin ?5?1 and ?v?6 will be summarized and discussed.
Authors with CRIS profile
Simone Maschauer
Professur für Molekulare Bildgebung und Radiochemie
Olaf Prante
Professur für Molekulare Bildgebung und Radiochemie
Involved external institutions
Austria (AT)How to cite
APA:
Haubner, R., Maschauer, S., & Prante, O. (2014). PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. BioMed Research International, 2014, 871609. https://doi.org/10.1155/2014/871609
MLA:
Haubner, Roland, Simone Maschauer, and Olaf Prante. "PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments." BioMed Research International 2014 (2014): 871609.
BibTeX: Download